Literature DB >> 24970039

Additive effect of PTH (1-34) and zoledronate in the prevention of disuse osteopenia in rats.

Jens Bay Vegger1, Esben Sommer Nielsen2, Annemarie Brüel3, Jesper Skovhus Thomsen4.   

Abstract

Immobilization is known to cause a rapid bone loss due to increased osteoclastic bone resorption and decreased osteoblastic bone formation. Zoledronate (Zln) is a potent anti-resorptive pharmaceutical, while intermittent PTH is a potent bone anabolic agent. The aim of the present study was to investigate whether PTH or Zln alone or in combination could prevent immobilization-induced osteopenia. Immobilization was achieved by injecting 4IU Botox (BTX) into the right hind limb musculature. Seventy-two 16-week-old female Wistar rats were randomized into 6 groups; baseline (Base), control (Ctrl), BTX, BTX+PTH, BTX+Zln, and BTX+PTH+Zln. PTH (1-34) (80μg/kg) was given 5days/week and Zln (100μg/kg) was given once at study start. The animals were killed after 4weeks of treatment. The bone properties were evaluated using DEXA, μCT, dynamic bone histomorphometry, and mechanical testing. BTX resulted in lower femoral trabecular bone volume fraction (BV/TV) (-25%, p<0.05), lower tibial trabecular bone formation rate (BFR/BS) (-29%, p<0.05), and lower bone strength (Fmax) at the distal femur (-19%, p<0.001) compared with Ctrl. BTX+PTH resulted in higher femoral BV/TV (+31%, p<0.05), higher tibial trabecular BFR/BS (+297%, p<0.05), and higher Fmax at the distal femur (+11%, p<0.05) compared with BTX. BTX+Zln resulted in higher femoral BV/TV (+36%, p<0.05), lower tibial trabecular BFR/BS (-93%, p<0.05), and higher Fmax at the distal femur (+10%, p<0.05) compared with BTX. BTX+PTH+Zln resulted in higher femoral BV/TV (+70%, p<0.001), higher tibial trabecular BFR/BS (+59%, p<0.05), and higher Fmax at the distal femur (+32%, p<0.001) compared with BTX. In conclusion, BTX-induced immobilization led to lower BV/TV, BFR/BS, and Fmax. In general, PTH or Zln alone prevented the BTX-induced osteopenia, whereas PTH and Zln given in combination not only prevented, but also increased BV/TV and BFR/BS, and maintained Fmax at the distal femoral metaphysis compared with Ctrl.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Biomechanics; Bisphosphonate; Histomorphometry; Immobilization; MicroCT; PTH

Mesh:

Substances:

Year:  2014        PMID: 24970039     DOI: 10.1016/j.bone.2014.06.020

Source DB:  PubMed          Journal:  Bone        ISSN: 1873-2763            Impact factor:   4.398


  15 in total

1.  The individual and combined effects of spaceflight radiation and microgravity on biologic systems and functional outcomes.

Authors:  Jeffrey S Willey; Richard A Britten; Elizabeth Blaber; Candice G T Tahimic; Jeffrey Chancellor; Marie Mortreux; Larry D Sanford; Angela J Kubik; Michael D Delp; Xiao Wen Mao
Journal:  J Environ Sci Health C Toxicol Carcinog       Date:  2021

Review 2.  Botulinum Toxin A and Osteosarcopenia in Experimental Animals: A Scoping Review.

Authors:  Min Jia Tang; H Kerr Graham; Kelsey E Davidson
Journal:  Toxins (Basel)       Date:  2021-03-14       Impact factor: 4.546

3.  The effect of strontium ranelate on the healing of a fractured ulna with bone gap in rabbit.

Authors:  Mohd Rafiq Mohd Ibrahim; Simmrat Singh; Azhar Mahmood Merican; Hanumantha Rao Balaji Raghavendran; Malliga Raman Murali; Sangeetha Vasudevaraj Naveen; Tunku Kamarul
Journal:  BMC Vet Res       Date:  2016-06-16       Impact factor: 2.741

4.  Alterations in gene expression precede sarcopenia and osteopenia in botulinum toxin immobilized mice.

Authors:  J B Vegger; A Brüel; A F Dahlgaard; J S Thomsen
Journal:  J Musculoskelet Neuronal Interact       Date:  2016-12-14       Impact factor: 2.041

5.  Sequential treatment with zoledronic acid followed by teriparatide or vice versa increases bone mineral density and bone strength in ovariectomized rats.

Authors:  T Shimizu; T Tanaka; T Kobayashi; I Kudo; M Nakatsugawa; A Takakura; R Takao-Kawabata; T Ishizuya
Journal:  Bone Rep       Date:  2017-08-19

6.  Immobilization induced osteopenia is strain specific in mice.

Authors:  Andreas Lodberg; Jens Bay Vegger; Michael Vinkel Jensen; Christian Mirian Larsen; Jesper Skovhus Thomsen; Annemarie Brüel
Journal:  Bone Rep       Date:  2015-04-17

7.  Zoledronic acid prevents disuse osteopenia and augments gene expression of osteoclastic differentiation markers in mice.

Authors:  Jens Bay Vegger; Annemarie Brüel; Jesper Skovhus Thomsen
Journal:  J Musculoskelet Neuronal Interact       Date:  2018-06-01       Impact factor: 2.041

8.  Antiresorptive Agents are More Effective in Preventing Titanium Particle-Induced Calvarial Osteolysis in Ovariectomized Mice Than Anabolic Agents in Short-Term Administration.

Authors:  Guangtao Fu; Shixun Li; Nengtai Ouyang; Junyan Wu; Changchuan Li; Wei Liu; Junxiong Qiu; Peng Peng; Ling Qin; Yue Ding
Journal:  Artif Organs       Date:  2018-09       Impact factor: 3.094

9.  Combination Therapy with Zoledronic Acid and Parathyroid Hormone Improves Bone Architecture and Strength following a Clinically-Relevant Dose of Stereotactic Radiation Therapy for the Local Treatment of Canine Osteosarcoma in Athymic Rats.

Authors:  Ryan C Curtis; James T Custis; Nicole P Ehrhart; E J Ehrhart; Keith W Condon; Sara E Gookin; Seth W Donahue
Journal:  PLoS One       Date:  2016-06-22       Impact factor: 3.240

10.  Pantoprazole, a proton pump inhibitor, does not prevent botulinum toxin induced disuse osteopenia in mice.

Authors:  J B Vegger; A Brüel; J S Thomsen
Journal:  J Musculoskelet Neuronal Interact       Date:  2017-09-01       Impact factor: 2.041

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.